Investigational. In clinical development, not approved. Material sold as a research chemical is not the trial drug. Educational only — not medical advice.
What it is
CagriSema is an investigational co-formulation of cagrilintide (amylin analog) and semaglutide (GLP-1).
Proposed mechanism
It combines two complementary satiety pathways — amylin and GLP-1 — for greater weight effect than either alone.1
State of the evidence
Phase 3 program; not yet approved.
Regulatory & status
Investigational; not approved.
Reconstitution (reference only)
Lab-handling reference only — not a preparation or dosing instruction: 1.5 mL (150 units) reconstitution solution per 5/5 mg vial. See the reconstitution calculator for the arithmetic. This page does not provide dosing guidance.
For educational and research purposes only. This content is not medical advice. Compounds referenced are research use only and not intended to diagnose, treat, cure, or prevent any disease. Free Peptide University does not sell compounds.